Monthly Archives: May 2016

ProLungdx Board Names Dr. John C. Ruckdeschel as Newest Board Memeber

Salt Lake City, Utah, May 25, 2016 – The Board of Directors of Fresh Medical Laboratories Inc., doing business as ProLungdx, today announced the appointment of Dr. John C. Ruckdeschel, M.D. to serve as a Director on the Company’s Board of Directors.  Dr. Ruckdeschel is a renowned oncologist with a career-long focus on thoracic malignancies and lung cancer.  Dr. Ruckdeschel formerly served as the Medical Director of Clinical Oncology at Intermountain Healthcare in Salt Lake City, Utah, the CEO of Moffitt Cancer Center and is a current member of the Medical Advisory Board of Prolungdx.

“ProLungdx will benefit immensely from the experience Dr. Ruckdeschel offers,” said Steven Eror, President and CEO of ProLungdx.  “We are pleased to expand his involvement to our Board of Directors, and we are confident his expertise will help bring our novel technology to those who need it most.”

Dr. Ruckdeschel received his B.S. degree in Biology from Rensselaer Polytechnic Institute and his MD from Albany Medical College in New York.  He trained as an intern at John Hopkins Medical Center, fulfilled a residency at Boston’s Beth Israel Hospital and completed a fellowship at the National Cancer Institute in Washington D.C.  He is a fellow of the American College of Physicians as well as the American College of Chest Physicians.  Dr. Ruckdeschel is also a well accomplished writer and presenter.  He has written and co-written more than 350 publications, book chapters and abstracts and has given more than 250 invited presentations.

Dr. Ruckdeschel served on the staff at Albany Medical College for a decade beginning in 1991, before he assumed the role of CEO and Director of the Moffitt Cancer Center in Tampa, FL.  In 2001, he became CEO and Director of Karmanos […]

By |25 May 2016|Press|Comments Off on ProLungdx Board Names Dr. John C. Ruckdeschel as Newest Board Memeber|

ProLungdx Announces Todd Morgan as Chairman of the Board

Salt Lake City, Utah, May 19, 2016 – Fresh Medical Laboratories, Inc, doing business as ProLungdx™, announced today that its board has appointed Todd Morgan as Chairman of the Board of Directors.  Mr. Morgan succeeds Clark Campbell, who served as the Chairman from 2012 to 2016.  Todd Morgan has been a Director since 2014 and begins his role as Chairman while ProLungdx markets its Electro Pulmonary Nodule Scanner (EPN Scan)â in Europe and seeks FDA approval in the US.

“Todd Morgan is an extraordinarily successful entrepreneur. He brings senior management ability with business and banking board experience,” said Steven Eror, President and CEO of ProLungdx.  “His leadership will help guide ProLungdx through our next period of growth and expansion.”

Mr. Morgan is a successful and widely respected businessman.  He began his career with The West Bend Company in the sales department and served as the District Manager.  He started Morgan Industries, an asphalt paving and maintenance business, growing it from one employee to 150 employees with offices in Utah and Arizona, and contracting in seven western states.  Mr. Morgan also started NuRock, a company which manufactures asphalt maintenance products.  He formed MPM Investment Group LP and currently serves as general partner and manager.  Mr. Morgan served on the Board of Directors of America West Bank and is a current member of the Board of Directors of Ellison Ranching Company.

About ProLungdx

ProLungdx is a privately held, US-based medical technology company that develops, manufactures and sells non-invasive medical technology to aid in the early detection and diagnosis of lung cancer.  The EPN Scan is approved for sale in the European Economic Area and is for investigational use only in the US.

For more information, contact:

C. Lindsay McSweeney

801-308-8861

info@prolungdx.com

By |19 May 2016|Uncategorized|Comments Off on ProLungdx Announces Todd Morgan as Chairman of the Board|

ProLungdx EPN Scan® Confirms Performance in Early Lung Cancer Risk Assessment

Salt Lake City, Utah, USA, May 18, 2016 – Fresh Medical Laboratories, Inc., doing business as ProLungdx™, today announced the initial results of its ongoing European Lung Cancer Registry.  When the Electro Pulmonary Nodule (EPN) Scan was administered to patients with lung nodules suspicious for cancer, the scan demonstrated results consistent with earlier research performed at Johns Hopkins and published in the Journal of Thoracic Oncology.  The non-invasive test correctly identified 23 out of 27, or 85% of patients where malignancy was confirmed by tissue biopsy.  More results are expected soon, as the EPN Scan has been administered to more than 170 patients in Europe and over 100 of these are enrolled in the registry.  Other research is underway at eight cancer centers in the US and four in Asia.

“The key to improved survival is understanding the risk associated with a suspicious pulmonary nodule.  It’s heartening to see such positive results coming from leading European interventional pulmonologists.  They are pioneers focused on immediate evaluation of indeterminate lung nodules.  Compared with the standard of care, we believe that the EPN Scan can increase the time available for treatment and may ultimately save lives,” said Steven Eror, President and CEO of ProLungdx.

The EPN Scan uses its novel mass averaging bioconductance technology to evaluate patients who discover lung nodules incidentally or by lung cancer screening.  As the low-dose computed tomography (LDCT) screen becomes widespread, risk stratification tools, such as ProLungdx’s EPN Scan, will be essential to aiding physicians to evaluate the risk of cancer while treatment options are still available.

About ProLungdx

ProLungdx is a privately held, US-based medical technology company that develops, manufactures and sells non-invasive medical technology to aid in the early detection and diagnosis of lung […]

By |18 May 2016|Press|Comments Off on ProLungdx EPN Scan® Confirms Performance in Early Lung Cancer Risk Assessment|